Cancer Cachexia Market Size, Industry Share, Report 2023-2028

3 minutes, 11 seconds Read

IMARC Group, a leading market research company, has recently releases report titled “Cancer Cachexia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global cancer cachexia market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Cancer cachexia is a serious condition generally observed in cancer patients that causes severe weight loss, muscle wasting, loss of appetite, and overall decline in physical functioning. It is more prevalent in advanced stages of cancer and can impact the quality of life of patients, treatment response, and overall prognosis. It is caused due to the occurrence of various chronic diseases, such as tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and multiple sclerosis. Besides this, it can be treated through nutritional interventions, pharmacological interventions, and exercise and physical therapy.

The global cancer cachexia market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2023-2028.

Request Free Sample Copy of This Report: https://www.imarcgroup.com/cancer-cachexia-market/requestsample

What are the growth prospects and trends in the cancer cachexia industry?

At present, the increasing prevalence of cancer among the masses across the globe represents one of the primary factors impelling the growth of the market. Apart from this, the growing demand for cancer cachexia treatment solutions among the geriatric population, as they have a reduced ability to tolerate aggressive cancer treatments, is positively influencing the market outlook.

Additionally, the rising emergence of novel therapies that focus on improving muscle mass, appetite stimulation, and overall patient well-being is strengthening the growth of the market. Besides this, the increasing focus on personalized medicine among the masses around the world is bolstering the growth of the market.

Furthermore, the rising awareness about the availability of novel therapeutic drugs to treat cancer cachexia among individuals is supporting the growth of the market.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Therapeutics:

  •  Progestogens
  • Corticosteroids
  • Combination Therapy
  • Others

Breakup by Mode of Action:

  • Appetite Stimulators
  • Weight Loss Stabilizers

Breakup by Distribution Channel:

  • Hospital Stores
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: [email protected]

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/

Similar Posts